Neuromyelitis Optica (NMO)Phase 3NCT02073279
Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
A Phase 3 study testing Satralizumab in people with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD), run by Hoffmann-La Roche at 58 sites in 15 countries.
Trial summary
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD. Read more about this study
- Who is it for?
- Ages 18 to 74 years
- Conditions the study is for
- Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
- What is being tested?
- Satralizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 95 participants
- Where
- 58 sitesin 15 countries
- Study dates
- 5 Aug 2014to 31 Jan 2022
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants must be diagnosed as having either neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD), defined as the following:
- NMO as defined by Wingerchuk et al. 2006 criteria (requires all of the following 3 criteria: I. Optic neuritis, II. Acute myelitis, III. At least two of three supportive criteria: Contiguous spinal cord lesion identified on a magnetic resonance imaging [MRI] scan extending over 3 vertebral segments; Brain MRI not meeting diagnostic criteria for multiple sclerosis [MS]; NMO-IgG seropositive status)
- NMOSD as defined by either of following criteria with anti-aquaporin-4 (AQP4) antibody seropositive status at screening: i. Idiopathic single or recurrent events of longitudinally extensive myelitis (≥3 vertebral segment spinal cord MRI lesion); ii. Optic neuritis, single, recurrent or simultaneous bilateral
- Clinical evidence of at least 1 documented relapse (including first attack) in last 12 months prior to screening
- Expanded Disability Status Scale (EDSS) score from 0 to 6.5 inclusive at screening
- Age 18 to 74 years, inclusive at the time of informed consent
- Ability and willingness to provide written informed consent and to comply with the requirements of the protocol
Who cannot join
- Clinical relapse onset (including first attack) within 30 days prior to baseline
- Exclusion Criteria Related to Previous or Concomitant Therapy:
- Any previous treatment with interleukin 6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation or bone marrow transplantation at any time
- Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS) relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) within 6 months prior to baseline
- Any previous treatment with anti-CD4, cladribine, cyclophosphamide or mitoxantrone within 2 years prior to baseline
- Treatment with any investigational agent within 3 months prior to baseline
Show all 30Show fewer
- Exclusions for General Safety:
- Pregnancy or lactation.
- For participants of reproductive potential, a positive result from a serum pregnancy test at screening, or not willing to use reliable means of contraception (physical barrier [participants or partner] in conjunction with a spermicidal product, contraceptive pill, patch, injectables, intrauterine device or intrauterine system) during the treatment period and for at least 3 months after the last dose of study drug
- Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline
- Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy (PML)
- Evidence of serious uncontrolled concomitant diseases that may preclude participant participation, as described; Other nervous system disease, cardiovascular disease, hematologic/hematopoiesis disease, respiratory disease, muscular disease, endocrine disease, renal/urologic disease, digestive system disease, congenital or acquired severe immunodeficiency
- Known active infection (excluding fungal infections of nail beds or caries dentium) within 4 weeks prior to baseline
- Evidence of chronic active hepatitis B or C
- History of drug or alcohol abuse within 1 year prior to baseline
- History of diverticulitis that, in the Investigator's opinion, may lead to increased risk of complications such as lower gastrointestinal perforation
- Evidence of active tuberculosis (excluding participants receiving chemoprophylaxis for latent tuberculosis infection)
- Evidence of active interstitial lung disease
- Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline
- History of malignancy within the last 5 years, including solid tumors, hematologic malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas of the skin, or in situ carcinoma of the cervix uteri that have been completely excised and cured)
- History of severe allergic reaction to a biologic agent (e.g., shock, anaphylactic reactions)
- Active suicidal ideation within 6 months prior to screening, or history of suicide attempt within 3 years prior to screening
- History of Stevens-Johnson syndrome
- Following laboratory abnormalities at screening*.
- White blood cells <3.0 x10^3/microliter (μL)
- Absolute neutrophil count <2.0 x 10^3 /μL
- Absolute lymphocyte count <0.5 x 10^3 /μL
- Platelet count <10 x 10^4 /μL
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal.
- If retest is conducted, the last value of retest before randomization must meet study criteria.
Trial locations and contacts
58 sites in 15 countries.
58 sites in 15 countries
United States20 sites
University of Michigan Health System
Ann Arbor, Michigan, 48109-0666
University of Colorado Denver -; Neurology
Aurora, Colorado, 80045
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
The Neurological Institute PA
Charlotte, North Carolina, 28204
University of Chicago; Neurology
Chicago, Illinois, 60637
Columbus Research and Wellness
Columbus, Georgia, 31909
OhioHealth Research Institute
Columbus, Ohio, 43214
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
Wayne State University - Comp Clinic and MS. Center
Detroit, Michigan, 48201
University of Kansas Medical Center
Kansas City, Kansas, 66160
University of Miami UHealth Professional Arts Center
Miami, Florida, 33136
Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
Milwaukee, Wisconsin, 53215
Consultants in Neurology Ltd
Northbrook, Illinois, 60062
OSF Saint Francis Medical Center
Peoria, Illinois, 64637
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
MidAmerica Neuroscience Institute
Prairie Village, Kansas, 66206
Virginia Commonwealth University
Richmond, Virginia, 23219-1901
Central Texas Neurology Consultants
Round Rock, Texas, 78681
UT Medicine San Antonio
San Antonio, Texas, 78229
The MS Center of Vero Beach
Vero Beach, Florida, 32962
Ukraine9 sites
Miska Klinichna Likarnia №16
Dnipropetrovsk, Tavria Okruha, 49100
Ivano-Frankivska oblasna klinichna likarnia
Ivano-Frankivsk, KIEV Governorate, 76008
Ivano-Frankivska miska klinichna likarnia №1
Ivano-Frankivsk, KIEV Governorate, 76018
Kiev National Medical University
Kiev, KIEV Governorate, 3110
Municipal Foundation of Kyiv Regional Council " Kyiv Region
Kyiv, KIEV Governorate, 4107
KU "Odeskyi oblasnyi medychnyi tsentr psykhichnoho zdorovia"
Odesa, Tavria Okruha, 65006
Reginal clinical psyconeurological hospital
Ternopil, KIEV Governorate, 46014
Vinnytskyi natsionalnyi medychnyi universytet imeni M.I. Pyr
Vinnytsia, Poltava Governorate, 21005
Municipal Establishment "City Clinical Hospital #2; Neurology
Zaporozhya, Poltava Governorate, 69068
Bulgaria5 sites
Medical Help Center EOOD
Dobrich, 9300
MMA-MHAT Pleven - Clinic for Neurology
Pleven, 5800
UMHAT 'Dr. Georgi Stranski', EAD
Pleven, 5800
MHATNP Sveti Naum EAD
Sofia, 1113
UMHAT Alexandrovska, EAD
Sofia, 1431
South Korea4 sites
Korea University Anam Hospital - Neurology
Seoul, 02841
Seoul National University Hospital
Seoul, 03080
Asan Medical Center
Seoul, 05505
Severance Hospital - Yonsei University Health System - Neurology
Seoul, 3722
Canada3 sites
Recherche Sepmus Inc.
Greenfield Park, Quebec, J4V 2J2
Centre hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, H2X 0A9
MS Clinical Trials Group
Vancouver, British Columbia, V6T 1Z3
Georgia3 sites
LTD Helsicore
Tbilisi, 0112
Pineo Medical Ecosystem LTD
Tbilisi, 0114
S.Khechinashvili Tbilisi State Medical University Clinic Ne
Tbilisi, 0179
Taiwan3 sites
China Medical University Healthcare System
Taichung, 40447
National Cheng Kung University Hospital; Neurology
Tainan, 704
Taipei Veterans General Hospital-Neurology
Taipei, 11217
Malaysia2 sites
Hospital Kuala Lumpur
Kuala Lumpur, 50586
Hospital Universiti Sains Malaysia [Neurology]
Kubang Kerian, Kelantan, 16150
Poland2 sites
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS
Katowice, 40-123
Miedzyleski Szpital Specjalistyczny w Warszawie
Warsaw, 04-749
Turkey (Türkiye)2 sites
Bilim University Medical Faculty Florence Nightingale Hospital
Istanbul, 34333
Ondokuz Mayis Univ. Med. Fac.
Samsun, 55139
Italy1 site
PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
Catania, Sicily, 95123
About this study
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
- Being tested
- Satralizumab, Placebo
- Medical subject headings
- Neuromyelitis Optica
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SatralizumabDrug
Also called SA237, RG6168
Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
PlaceboDrug
Placebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W).
| Study group | Role | What they receive |
|---|---|---|
| Satralizumab | Experimental | Participants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study. Receives: Drug: Satralizumab |
| Placebo | Placebo comparator | Participants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study. Receives: Drug: Satralizumab; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period
TFR was defined as time from randomization to first occurrence of relapse in the DB period. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse.
Measured: Up to Week 216
Secondary outcomes (31)
Change From Baseline to Week 24 in Visual Analogue Scale (VAS) for Pain During the DB Period
The VAS is a subjective measure of pain consisting of a 100 mm line with two endpoints representing 0 = "no pain" and 100 = "pain as bad as it could be". Participants rated their pain by placing a mark on the line corresponding to their current level of pain. The distance along the line from the "no pain" marker was measured with a ruler giving a pain score out of 100. A higher score indicated more pain and lower scores reflected a better health state. A negative change from baseline indicates an improvement. ANCOVA was used for analysis to report the adjusted mean and standard error (SE).
Measured: Baseline, Week 24
Change From Baseline to Week 24 in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale During the DB Period
The FACIT Fatigue scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days. As each of the 13 items of the scale ranges from 0-4, the range of possible scores was computed using FACIT scoring algorithm as 0-52, where 0 is the worst possible score and 52 the best which indicated less fatigue. A positive change from baseline indicates an improvement.
Measured: Baseline, Week 24
Relapse-Free Rate During the DB Period
Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onsets within 30 days of one another, they were counted as 1), and onset date used in analysis was the date of first relapse.
Measured: Up to Week 216
Annualized Relapse Rate (ARR) During the DB Period
The ARR is calculated as the total number of participants with adjudicated PDRs experienced divided by the patient-years at risk. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological NMO or NMOSD. Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (2 relapses with onset days in 30 days of one another was counted as 1 relapse), onset date used in analysis was the date of first relapse.
Measured: Up to Week 216
Change From Baseline in Short Form Generic Health Survey (SF-36) Bodily Pain Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health component summary measures and a preference-based health utility index. The domain scores were transformed to a 0-100 scale, where higher scores indicate better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Mental Component Summary Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period
The SF-36v2 is a multi-purpose, short form health survey with 36 questions. It has 8 domains (vitality, physical functioning, bodily pain, general health, role-physical, role emotional, social role functioning and mental health) of functional health and well-being scores as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. The component scores were transformed to a 0-100 scale, where higher score indicates better quality of life. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period
The EQ-5D is a participant-answered questionnaire measuring 5 dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression with 3 possible response categories: 1) no problems; 2) some problems; 3) severe problems. The scores from 5 dimensions are used as input to generate EQ-5D index score using scoring algorithm. The EQ-5D index score is scored on a scale of -0.2 to 1. A higher score reflects a better health state. A positive change from baseline indicates an improvement
Measured: Baseline up to Week 216
Change From Baseline in Speed of Timed 25-Foot Walk (T25W) at 24 Week Intervals During the DB Period
The T25W is an assessment of walking ability. The time (in seconds) that the participant took to walk 25 feet was measured. Speed is calculated as 1/Timed 25-Foot Walk where time is measured in seconds. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period
The mRS is a 7-point disability scale that assesses the degree of disability in participants with neurological impairment. Possible scores range from 0 (no symptoms at all) up to 6 (death). Higher scores reflect increased disability. A negative change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period
The ZBI is the measurement to assess caregiver burden. The 22 items ask for the strain caregivers perceive. Responses range from 0 (never) to 4 (nearly always). The overall ZBI score ranges from 0 to 88. The higher the total score, the heavier the perceived burden. A negative change from baseline indicates an improvement.
Measured: Baseline up to Week 120
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period
The EDSS is an ordinal scale with values from 0 points (normal neurological examination) to 10 points (death) increasing in half-point increments once an EDSS of 1.0 has been reached. Higher scores represent increased disability. A negative change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period
Visual acuity was measured using Snellen 20-foot wall chart and then converted to logMAR visual acuity scoring. Lower values indicate better visual acuity. Data are reported for right eye (OD) and left eye (OS). A negative change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Change From Baseline in Visual Function (Low-Contrast Sloan Letter Chart [LCSLC]) Scores at 24 Week Intervals During the DB Period
The LCSLC evaluates the visual function and captures the minimum size at which individuals can perceive letters of a particular contrast level. The change in binocular visual acuity, as assessed by the number of letters read correctly from a distance of 2 meters on 100%, 2.5% and 1.25% contrast level Sloan letter charts, was analyzed. The LCSLC is scored on a scale of 0-60. Higher scores indicate better visual function. A positive change from baseline indicates an improvement.
Measured: Baseline up to Week 216
Number of Participants With at Least One Adverse Event in the DB Period
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study are also considered as adverse events.
Measured: Up to Week 216
Number of Participants With at Least One Serious Adverse Event in the DB Period
A serious adverse event is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is medically significant or requires intervention to prevent one or other of the outcomes listed above.
Measured: Up to Week 216
Number of Participants With Non-Serious Adverse Events of Special Interest in the DB Period
Non-serious adverse events of special interest for this study included:
- cases of an elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in combination with either an elevated bilirubin or clinical jaundice, 2) suspected transmission of an infectious agent by the study treatment.
Measured: Up to Week 216
Number of Participants With Selected Adverse Events in the DB Period
Selected adverse events for this study included:
- all infections, 2) serious infections, 3) potential opportunistic infections, 4) injection-related reactions (IRRs; an AE which occured within 24 hours after study treatment injection except where the event was not considered an allergic reaction), 5) psychiatric disorders and 6) anaphylaxis (an acute allergic/hypersensitivity reaction).
Measured: Up to Week 216
Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period
The Columbia-Suicide Severity Rating Scale (C-SSRS) is an assessment tool to evaluate suicidal ideation and behavior. Categories have binary responses (yes/no) and include: Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation or behavior is indicated by a "yes" answer to any of the listed categories. A score of 0 is assigned if no suicide risk is present. A score of 1 or higher indicates suicidal ideation or behavior.
Measured: Baseline and Post-Baseline (up to Week 216)
Serum Satralizumab Concentration During the DB Period
Measured: Baseline, Weeks 2, 4, 5, 6, 8, and every 4 weeks thereafter up to Week 204
Serum Interleukin-6 (IL-6) Concentration During the DB Period
Measured: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period
Measured: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period
Measured: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Percentage of Participants With Anti-Drug Antibodies to Satralizumab in the DB Period
Reported here is the percentage of participants with at least one positive anti-drug antibody measurement during the DB period.
Measured: Up to approximately Week 216
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2014 (estimated)
- Study start5 Aug 2014
- Primary completion12 Oct 2018
- Study completion31 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Neuromyelitis Optica (NMO)Studies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 95 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Chugai Pharmaceutical
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02073279
- Sponsor's protocol ID
- BN40900
- Other IDs
- SA-309JG, 2015-005431-41, 2015
- Status last verified
- Jan 2023
- First submitted
- 25 Feb 2014
- Last updated
- 1 Mar 2023
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200450. doi: 10.1212/NXI.0000000000200450. Epub 2025 Jul 31.
PubMed 40743487Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, Palace J, Blondeau K, Burdeska A, Ngwa I, Klingelschmitt G, Triyatni M, Yamamura T. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025 Jul;99:106444. doi: 10.1016/j.msard.2025.106444. Epub 2025 Apr 19.
PubMed 40288333Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Budingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan.
PubMed 36724181Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Budingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Oct;66:104025. doi: 10.1016/j.msard.2022.104025. Epub 2022 Jul 5.
PubMed 36007339Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8.
PubMed 32333898
Study at a glance
From the registry record, last updated by the sponsor on 1 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab (SA237) as Monotherapy in Patients With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
- ClinicalTrials.gov ID
- NCT02073279
- Acronym / sponsor ID
- BN40900
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 95 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Collaborators
- Chugai Pharmaceutical
- Study start
- 5 Aug 2014 (actual)
- Primary completion
- 12 Oct 2018 (actual)
- Study completion
- 31 Jan 2022 (actual)
- First posted
- 27 Feb 2014 (estimated)
- Results
- Posted 31 Dec 2020
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Satralizumab | Experimental | Drug: SatralizumabParticipants randomized to this arm for the double-blind period will receive satralizumab monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study. |
| Placebo | Placebo comparator | Drug: Satralizumab, Drug: PlaceboParticipants randomized to this arm for the double-blind period will receive placebo monotherapy. The double-blind period for the participant ends either when the participant experiences a Clinical Endpoint Committee (CEC) confirmed protocol-defined relapse, the total number of CEC confirmed protocol-defined relapses reaches 44, or 1.5 years after the last patient was randomized.. In the open-label extension period, the participant will receive satralizumab SC injection at Weeks 0, 2, and 4, and Q4W thereafter, up to the end of the study. |
Who may qualify
- Ages
- 18 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Participants must be diagnosed as having either neuromyelitis optica (NMO) or NMO spectrum disorder (NMOSD), defined as the following:
- Clinical evidence of at least 1 documented relapse (including first attack) in last 12 months prior to screening
- Expanded Disability Status Scale (EDSS) score from 0 to 6.5 inclusive at screening
- Age 18 to 74 years, inclusive at the time of informed consent
- Ability and willingness to provide written informed consent and to comply with the requirements of the protocol
Key exclusion criteria (30 listed)
- Clinical relapse onset (including first attack) within 30 days prior to baseline
- Any previous treatment with interleukin 6 (IL-6) inhibitory therapy (e.g., tocilizumab), alemtuzumab, total body irradiation or bone marrow transplantation at any time
- Any previous treatment with anti-CD20, eculizumab, anti-BLyS monoclonal antibody (e.g., belimumab), any other treatment for prevention of multiple sclerosis (MS) relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate) within 6 months prior to baseline
- Any previous treatment with anti-CD4, cladribine, cyclophosphamide or mitoxantrone within 2 years prior to baseline
- Treatment with any investigational agent within 3 months prior to baseline
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SatralizumabAlso: SA237, RG6168Satralizumab will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W). | Drug | Placebo, Satralizumab |
| PlaceboPlacebo will be administered subcutaneously (SC) at Weeks 0, 2, and 4, and thereafter once every 4 weeks (Q4W). | Drug | Placebo |
Primary outcome
Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period
Time frame: Up to Week 216
TFR was defined as time from randomization to first occurrence of relapse in the DB period. Protocol-defined relapse was occurrence of new or worsening neurological symptoms attributable to neurological neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD). Symptoms had to persist for >24 hours and not be attributable to confounding clinical factors (e.g., fever, infection, injury, change in mood, adverse reactions to medications). New or worsening neurological symptoms that occurred < 31 days following onset of a protocol-defined relapse were considered part of same relapse (i.e., if 2 relapses had onset days that were 30 days of one another, they were counted only as 1 relapse), and onset date used in analysis was the date of first relapse.
31 secondary outcomes
Change From Baseline to Week 24 in Visual Analogue Scale (VAS) for Pain During the DB Period
Time frame: Baseline, Week 24
Change From Baseline to Week 24 in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale During the DB Period
Time frame: Baseline, Week 24
Relapse-Free Rate During the DB Period
Time frame: Up to Week 216
Annualized Relapse Rate (ARR) During the DB Period
Time frame: Up to Week 216
Change From Baseline in Short Form Generic Health Survey (SF-36) Bodily Pain Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 General Health Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Mental Health Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Physical Functioning Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Role-Emotional Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Role-Physical Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Social Role Functioning Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Vitality Domain Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Mental Component Summary Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in SF-36 Physical Component Summary Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in EuroQoL-5 Dimensions (EQ-5D) Index Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in Speed of Timed 25-Foot Walk (T25W) at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in Modified Rankin Scale (mRS) Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in Zarit Burden Interview (ZBI) Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 120
Change From Baseline in Expanded Disability Status Scale (EDSS) Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in Visual Acuity (Snellen Chart) at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Change From Baseline in Visual Function (Low-Contrast Sloan Letter Chart [LCSLC]) Scores at 24 Week Intervals During the DB Period
Time frame: Baseline up to Week 216
Number of Participants With at Least One Adverse Event in the DB Period
Time frame: Up to Week 216
Number of Participants With at Least One Serious Adverse Event in the DB Period
Time frame: Up to Week 216
Number of Participants With Non-Serious Adverse Events of Special Interest in the DB Period
Time frame: Up to Week 216
Number of Participants With Selected Adverse Events in the DB Period
Time frame: Up to Week 216
Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia-Suicide Severity Rating Scale in the DB Period
Time frame: Baseline and Post-Baseline (up to Week 216)
Serum Satralizumab Concentration During the DB Period
Time frame: Baseline, Weeks 2, 4, 5, 6, 8, and every 4 weeks thereafter up to Week 204
Serum Interleukin-6 (IL-6) Concentration During the DB Period
Time frame: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Serum Soluble IL-6 Receptor (sIL-6R) Concentration During the DB Period
Time frame: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Serum High Sensitivity C-Reactive Protein (hsCRP) Concentration During the DB Period
Time frame: Baseline, Weeks 2, 4, and every 4 weeks thereafter up to Week 216
Percentage of Participants With Anti-Drug Antibodies to Satralizumab in the DB Period
Time frame: Up to approximately Week 216
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Mar 2023.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 40743487Bennett JL, Fujihara K, Saiz A, Traboulsee AL, Greenberg BM, Weinshenker BG, Patti F, Kleiter I, Palace J, De Seze J, Evans R, Blondeau K, Klingelschmitt G, Vodopivec I, Rahim M, Yamamura T. Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study. Neurol Neuroimmunol Neuroinflamm. 2025 Sep;12(5):e200450. doi: 10.1212/NXI.0000000000200450. Epub 2025 Jul 31.
- Derived from this study: PubMed 40288333Greenberg BM, Fujihara K, Weinshenker B, Patti F, Kleiter I, Bennett JL, Palace J, Blondeau K, Burdeska A, Ngwa I, Klingelschmitt G, Triyatni M, Yamamura T. Analysis of infection rates in neuromyelitis optica spectrum disorder: Comparing satralizumab treatment in SAkuraMoon, post-marketing, and US-based health claims data. Mult Scler Relat Disord. 2025 Jul;99:106444. doi: 10.1016/j.msard.2025.106444. Epub 2025 Apr 19.
- Derived from this study: PubMed 36724181Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Budingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan.
- Derived from this study: PubMed 36007339Yamamura T, Weinshenker B, Yeaman MR, De Seze J, Patti F, Lobo P, von Budingen HC, Kou X, Weber K, Greenberg B. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult Scler Relat Disord. 2022 Oct;66:104025. doi: 10.1016/j.msard.2022.104025. Epub 2022 Jul 5.
- Derived from this study: PubMed 32333898Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8.
Related trials for Neuromyelitis Optica (NMO)
RecruitingPhase 1/2
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder
Active, not recruitingPhase 1
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NMO Spectrum Disorder
Active, not recruitingPhase 2/3
Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
Neuromyelitis Optica Spectrum Disorder
RecruitingObservational study
Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)
NMO Spectrum Disorder, MRI
Active, not recruitingPhase 2
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
Neuromyelitis Optica Spectrum Disorder Attack
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
58 sites in 15 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Satralizumab in people with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD), run by Hoffmann-La Roche at 58 sites in 15 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 58 sites in United States, Ukraine, Bulgaria, South Korea, Canada and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 31 Dec 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period (time frame: Up to Week 216). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02073279, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Mar 2023.